Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-04-19
2011-04-19
Vivlemore, Tracy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500
Reexamination Certificate
active
07928084
ABSTRACT:
Disclosed are methods and compositions for preventing and treating conditions associated with platelet aggregation, comprising administering a therapeutically effective amount of a composition that modifies the interaction of DNAJC10 with αIIbβ3 in a megakaryocyte, thereby altering the expression of αIIbβ3 on the surface of the megakaryocyte.
REFERENCES:
Corazzari M et al. “Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57.” Br. J. Cancer 96:1062-1071, 2007.
Cunnea P et al. “Increased expression of specific thioredoxin family proteins: a pilot immunohistochemical study on human hepatocellular carcinoma.” Int. J. Immunopath. Pharmacol. 20:17-24, 2007.
Wilcox DA et al. “Megakaryocyte-targeted synthesis of the integrin beta3-subunit results in the phenotypic correction of Glanzmann thrombocytopenia.” Blood 95:3645-3652, 2000.
Chen A et al. “Proteomic analysis of the alphallbeta3 interatome reveals novel chaperone and trafficking proteins, including an HSP40 chaperone, DNAJC10, that regulations alphallbeta3 surface expression.” Blood 112:987-988, 2008.
Chen P et al. Differential display identifies genes in Chinese hamster ovary cells sensitive to elevated ammonium. Appl. Biochem. Biotechnol. 141:349-359, 2007.
Gu SH et al. “and identification of a novel cDNA which encodes a putative protein with a DnaJ domain and a thioredoxin active motif, human macrothioredoxin.” Biochem. Genet. 41:245-253, 2003.
Ushioda R et al. “ERdj5 is required as a disulfide reductase for degradation of misfolded proteins in the ER.” Science 321:569-572, 2008.
Cunnea PM et al. “ERdj5, an endoplasmic reticulum (ER)-resident protein containing DnaJ and thoredoxin domains, is expressed in secretory cells or following ER stress.” J. Biol. Chem. 278:1059-1066, 2003.
Dong M et al. “ERdj4 and ERdj5 are required for endoplasmic reticulum-associated protein degradation of misfolded surfactant protein C.” Mol. Biol. of the Cell 19:2620-2630, 2008.
Golden A et al. “Role of platelet membrane glycoprotein llb-llla in agonist-induced tryrosine phosphorylation of platelet proteins.” J. Cell Biol. 111:3117-3127, 1990.
Braakman I et al. “Biochemistry. Cargo load reduction.” Science 321:499-500, 2008.
Kolodzief Ma et al. “Study of the endoproteolytic cleavage of platelet glycopretein llb using oligonucleotide-mediated mutagenesis.” J. Biol. Chem. 266:23499-23504, 1991.
Plancon S et al. “Green Fluorescent protein (GFP) tagged to the cytoplasmic tail of alphallb or beta3 allows the expression of a fully functional integrin alphallbbeta3: effect of beta3-GFP on alphallbbeta3 ligand binding.” Biochem. J. 357:529-536, 2001.
Abyaneh Mahmoud Yazdani
Chen Amanda
Mitchell W. Beau
Bergman Michelle Glasky
Cullman Louis C.
K&L Gates LLP
New York Blood Center Inc.
Vivlemore Tracy
LandOfFree
Regulation of integrin surface expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Regulation of integrin surface expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regulation of integrin surface expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2719966